SCHEMBL5707178

SCHEMBL5707178

COC(=O)/C(Cl)=C/c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 4/20 0.53
MEN1 O00255 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
ALDH1A1 P00352 1/20 0.53
NPC1 O15118 3/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
GAA P10253 1/20 0.50
LMNA P02545 1/20 0.49
AKR1C3 P42330 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9486859 1.00 RAB9A (0.53) RAB9AKMT2AMAPTMEN1NPSR1
SCHEMBL10625694 1.00 RAB9A (0.53) RAB9AKMT2AMAPTMEN1NPSR1
SCHEMBL77732 0.82 MEN1 (0.63) KMT2AMAPTMEN1NPSR1AKR1C3
SCHEMBL6064517 0.81 ALDH1A1 (0.50) KMT2AMAPTNPSR1ALDH1A1NFKB1
SCHEMBL5747001 0.80 MEN1 (0.72) RAB9AKMT2AMAPTMEN1NPSR1
SCHEMBL4803624 0.80 MEN1 (0.72) RAB9AKMT2AMAPTMEN1NPSR1
SCHEMBL1221498 0.80 MEN1 (0.52) KMT2AMAPTMEN1NPSR1ALDH1A1
SCHEMBL6065568 0.80 HSD17B3 (0.46) RAB9AKMT2AMAPTMEN1ALDH1A1
SCHEMBL11007893 0.79 AKR1C3 (0.59) RAB9AKMT2AMAPTMEN1NPSR1
SCHEMBL18264401 0.79 AKR1C3 (0.59) RAB9AKMT2AMAPTMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718628-A1 CINNAMIC AMIDES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Active Biotech AB (SE) 2006-11-08 EP disclosed
US-7084281-B2 Synthesis of dihalohydrins and tri- and tetra-substituted olefins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-08-01 US disclosed
WO-2005080362-A1 CINNAMIC AMIDES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ACTIVE BIOTECH AB (SE) 2005-09-01 WO disclosed
US-20040143125-A1 Synthesis of dihalohydrins and tri- and tetra-substituted olefins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2004-07-22 US disclosed
EP-0198397-B1 METHOD OF PRODUCING L-PHENYLALANINE KURARAY CO., LTD. (JP) 1993-01-07 EP disclosed
US-4743547-A PURITY, ENZYME HYDROLYSIS KURARAY CO., LTD. (JP) 1988-05-10 US disclosed
EP-0198397-A2 Method of producing L-phenylalanine KURARAY CO., LTD. (JP) 1986-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040143125-A1 Synthesis of dihalohydrins and tri- and tetra-substituted olefins TALDO1, HDHD5, TKT RAB9A 4146/4885KMT2A 2083/4885MAPT 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.